Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Nephrology  |  Oncology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Blood Cancer Clinical Trials

A listing of Blood Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (1198) clinical trials

A Study to Investigate the Safety Tolerability Efficacy Pharmacokinetics and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)

The drug being tested in this study is called TAK-079. TAK-079 is being tested to treat people who have relapsed and/or refractory multiple myeloma (RRMM). This study will assess the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of TAK-079 monotherapy and will provide a preliminary assessment of its activity against MM. ...

Phase

Follow-Up Evaluation for Gene-Therapy-Related Delayed Adverse Events After Participation in Pediatric Oncology Branch Clinical Trials

Background Study subjects exposed to gene therapy interventions may be at risk for delayed or long term adverse consequences. The U.S. Food and Drug Administration (FDA) has issued Draft Guidance for Industry: Long Term Follow-up After Administration of Human Gene Therapy Products, which outlines a framework to assess the risk ...

Phase N/A

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Background Acute lymphoblastic leukemia (ALL) accounts for approximately 25% of childhood cancer. Survival rates have improved, but outcomes for some subgroups, including infants and young adults remain poor, and survival for patients who relapse is < 50%, despite allogeneic stem cell transplant following second remission. CD19 immune escape has been ...

Phase

A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma

This is a Phase 3, randomized (study medication assigned to participants by chance), open-label (identity of study drug will be known to participant and study staff), controlled study which consists of two parts: Part 1 and Part 2. The Part 1 is a pharmacokinetic run-in part, which will be conducted ...

Phase

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

This study is designed to evaluate the safety, tolerability, and antitumor activity of SEA-BCMA in adults with relapsed or refractory multiple myeloma (RRMM). The study will be conducted in 2 parts: Part 1 - Dose-escalation: Approximately 25 patients will be treated to evaluate the safety and tolerability of SEA-BCMA, and ...

Phase

T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

Background Improved treatments for a variety of treatment-resistant malignancies including B-cell lymphomas, and chronic lymphocytic leukemia (CLL) and Hodgkin lymphoma are needed. A particular need is development of new treatments for chemotherapy-refractory B-cell malignancies. T cells can be genetically modified to express chimeric antigen receptors (CARs) that specifically target malignancy-associated ...

Phase

Collection of Peripheral Blood Mononuclear Cells (PBMCs) From Healthy People for the Expansion of T Cells for Adoptive Cell Therapy

Background Adoptive T cell therapies are being used to treat patients with cancer and hematological malignancies. Some of these therapies require that the patients T cells be expanded over 100-fold. This cell expansion can be accomplished by culturing autologous T cells with peripheral blood mononuclear cells (PBMCs) collected from healthy ...

Phase N/A

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

Background Multiple myeloma (MM) is a nearly always incurable malignancy of plasma cells. T cells can be genetically modified to express chimeric antigen receptors (CARs) that target malignancy-associated antigens. SLAMF7 is highly and uniformly expressed on MM cells but is absent on normal tissues except for some leukocytes, including a ...

Phase

Evaluation Treatment and Training for Patients With Blood Disorders

This protocol is designed to allow the evaluation, follow up, and standard medical care of patients (and when appropriate, their stem cell donor) with bone marrow failure states, cytopenias, metastatic solid tumors, or hematologic malignancies not currently entered on an active NHLBI protocol or not being screened for an active ...

Phase N/A

A Study of PLX2853 in Advanced Malignancies.

The purpose of this research study is to evaluate safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of the investigational drug PLX2853 in subjects with advanced malignancies.

Phase